Evaluating an orphan drug development partner takes a bit more scrutiny than a standard CRO, consultant, or commercialization partner because the stakes are higher: small patient populations, limited precedent, regulatory nuance, and often a strong need for scientific judgment that isn’t colored by sales incentives.

Here’s a practical way to assess whether the partner is credible and unbiased.

1) Check their disease-area depth, not just general experience

Look for evidence they have worked on:

• The same orphan indication, or a very close analogue
• Rare-disease regulatory pathways
• Small-N study design, natural history studies, and endpoint selection
• Biomarker strategy, patient identification, and feasibility challenges

Ask for:

• Specific programs they’ve supported in the last 5–10 years
• Published work, posters, or conference presentations
• Examples of decisions they made that changed a program’s direction

A credible partner should be able to discuss tradeoffs, not just successes.

2) Verify their track record independently

Don’t rely only on their slide deck.

Check:

• PubMed / Google Scholar publications
• ClinicalTrials.gov or EU Clinical Trials Register
• FDA/EMA approvals, orphan designations, meeting records if public
• Conference abstracts and advisory board participation
• Former client references, especially from companies of similar stage and size

Look for consistency between:

• What they say they did
• What public records show
• What references confirm

3) Assess whether they have financial or commercial conflicts

Bias often comes from incentives.

Red flags include:

• They represent multiple competing assets in the same rare disease
• They are paid by outcomes that favor moving a program forward regardless of data quality
• They have undisclosed ties to patient advocacy groups, KOLs, or vendors
• They also sell lab services, recruitment services, or licensing advisory where they may steer recommendations toward their own revenue streams

Ask:

• “What conflicts do you have in this disease area?”
• “Do you work with competitors or adjacent programs?”
• “How do you manage conflicts and disclose them?”

A credible partner will answer transparently.

4) Look for method discipline

Unbiased partners usually show strong process discipline.

In a good sign, they:

• Define hypotheses and decision criteria up front
• Use structured evidence reviews
• Distinguish data from opinion
• Quantify uncertainty
• Avoid overclaiming from weak signals
• Present alternative explanations and downside scenarios

Warning signs:

• “This will definitely work”
• Overly polished conclusions without data caveats
• Selective citation of only supportive studies
• Recommending expensive next steps before feasibility is established

5) Evaluate how they handle uncertainty in rare disease

Orphan drug development is full of ambiguity. Good partners don’t pretend otherwise.

Ask them how they would approach:

• Endpoint selection with limited history
• Natural history gaps
• Placebo ethics
• Small sample sizes and multiplicity
• Regulatory interactions when precedent is weak

A strong partner can explain:

• What is known
• What is assumed
• What would change their view

6) Ask for examples of when they were wrong

This is one of the best bias tests.

A credible partner should be able to share:

• A project that failed
• A hypothesis they initially supported but later abandoned
• A case where the data contradicted their recommendation

What you want to hear:

• They updated their view based on evidence
• They did not “spin” the result
• They learned and changed process

If they never admit uncertainty or mistakes, that’s a concern.

7) Evaluate the independence of their experts

If they rely heavily on KOLs, patient leaders, or regulatory advisors, ask:

• How were they selected?
• Are they compensated, and by whom?
• Do they have any equity or consulting arrangements?
• Are they connected to competitors or advocacy organizations?

You want advisors who are credible and diverse in perspective, not a closed network reinforcing a single viewpoint.

8) Review the quality of their written work

Ask for a sample deliverable:

• Development strategy
• Landscape assessment
• Trial design memo
• Regulatory briefing package
• Patient journey analysis

Look for:

• Clear sourcing
• Balanced pros/cons
• Explicit assumptions
• Practical recommendations
• Separation of facts, interpretation, and opinion

Poor-quality writing often reveals poor-quality thinking.

9) Understand who actually does the work

Sometimes the firm name is credible, but the assigned team is not.

Ask:

• Who will be the day-to-day lead?
• What is their exact rare-disease experience?
• Who reviews their work?
• Will senior experts be involved, or only in sales meetings?
• Can you interview the actual project team?

You’re evaluating people, not just the brand.

10) Test them with a structured case discussion

Give them a real or hypothetical orphan-drug scenario and see how they think.

For example:

• A first-in-class program with weak biomarker correlation
• A natural history dataset that is incomplete
• A feasibility issue in ultra-rare recruitment
• A competing therapy entering phase 3

Good partners will:

• Ask clarifying questions
• Identify key risks
• Suggest staged de-risking steps
• Avoid premature certainty

Bad partners will jump straight to a one-size-fits-all plan.

---

A simple scoring framework

You can rate each area 1–5:

1. Disease expertise
2. Regulatory/scientific credibility
3. Transparency about conflicts
4. Evidence-based reasoning
5. Quality of references and publications
6. Ability to acknowledge uncertainty
7. Independence of assigned team

A partner scoring low on transparency or methodological rigor is usually not worth the risk, even if they have strong credentials.

---

Key red flags

Be cautious if they:

• Make big claims without data
• Refuse to disclose conflicts
• Overstate patient access or KOL influence
• Use vague “proprietary” reasoning to avoid explaining methods
• Consistently recommend expensive programs that benefit their own revenue
• Dismiss regulatory or feasibility concerns too quickly
• Cannot produce named references or concrete deliverables

---

Best-practice due diligence steps

Before signing, you can:

• Run reference checks with former clients
• Request a sample work product
• Interview the actual project team
• Ask for disclosure of all conflicts
• Compare their recommendation against 1–2 independent experts
• Include milestone-based deliverables in the contract
• Require disclosure of assumptions and sources

---

If you want, I can also turn this into a one-page partner evaluation checklist or a scorecard template you can use in vendor selection.